巴西淋病奈瑟菌基因组流行病学近期动态:2017-20年与2015-16年抗菌药物耐药性及基因组谱系比较
该研究对巴西11个城市2017至2020年分离的623株淋病奈瑟菌进行全基因组测序,并与2015至2016年数据比较。结果显示阿奇霉素耐药率升至15.6%(97/623),主要由23S rRNA C2611T和mtr嵌合体克隆扩增所致;头孢曲松耐药率维持0%,头孢克肟耐药率为0.2%(1/623)。
要点
- 阿奇霉素耐药率15.6%(97/623),主要因23S rRNA C2611T和mtr嵌合体菌株克隆扩增。
- 头孢曲松耐药率0%,头孢克肟耐药率0.2%(1/623),与2015-16年持平。
- 未发现已知的zoliflodacin耐药gyrB突变或gepotidacin耐药gyrA突变。
核心结论
- 巴西阿奇霉素耐药率显著上升,主要由23S rRNA C2611T和mtrD嵌合/半嵌合体介导,多为低水平耐药,可能威胁推荐的 ceftriaxone-azithromycin 联合治疗,但缺乏头孢曲松耐药令人鼓舞。
- 巴西及拉丁美洲和加勒比国家亟需加强淋球菌抗菌药物耐药监测,包括全基因组测序。
研究设计与样本
- 对巴西11个城市2017至2020年分离的623株淋病奈瑟菌进行全基因组测序(Illumina NextSeq 550),并与2015至2016年巴西WGS及AMR数据比较。
- 采用琼脂稀释法/Etest测定抗菌药物耐药性,获得分子分型和耐药决定因子,分析基因组谱系与AMR的关联。
主要发现
- 阿奇霉素耐药率为15.6%(97/623),主要因携带23S rRNA C2611T(多为NG-STAR CC124)和mtr嵌合体(多为NG-STAR CC63、MLST ST9363)的菌株克隆扩增。
- 头孢曲松耐药率0%,头孢克肟耐药率0.2%(1/623),与2015-16年水平相同。
- 未发现已知的zoliflodacin耐药gyrB突变或gepotidacin耐药gyrA突变。
- 基因组谱系和亚谱系显示从亚谱系A5向亚谱系A1-A4的系统发育转变,而谱系B内的分离株在巴西仍保持多样性。
关键数值与推荐
- 阿奇霉素耐药判定依据未在摘要中详述。
- 头孢曲松耐药率0%(0/623),头孢克肟耐药率0.2%(1/623)。
- 阿奇霉素耐药率15.6%(97/623)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Regular quality-assured WGS with antimicrobial resistance (AMR) and epidemiological data of patients is imperative to elucidate the shifting gonorrhoea epidemiology, nationally and internationally. We describe the dynamics of the gonococcal population in 11 cities in Brazil between 2017 and 2020 and elucidate emerging and disappearing gonococcal lineages associated with AMR, compare to Brazilian WGS and AMR data from 2015 to 2016, and explain recent changes in gonococcal AMR and gonorrhoea epidemiology. METHODS: WGS was performed using Illumina NextSeq 550 and genomes of 623 gonococcal isolates were used for downstream analysis. Molecular typing and AMR determinants were obtained and links between genomic lineages and AMR (determined by agar dilution/Etest) examined. RESULTS: Azithromycin resistance (15.6%, 97/623) had substantially increased and was mainly explained by clonal expansions of strains with 23S rRNA C2611T (mostly NG-STAR CC124) and mtr mosaics (mostly NG-STAR CC63, MLST ST9363). Resistance to ceftriaxone and cefixime remained at the same levels as in 2015-16, i.e. at 0% and 0.2% (1/623), respectively. Regarding novel gonorrhoea treatments, no known zoliflodacin-resistance gyrB mutations or gepotidacin-resistance gyrA mutations were found. Genomic lineages and sublineages showed a phylogenomic shift from sublineage A5 to sublineages A1-A4, while isolates within lineage B remained diverse in Brazil. CONCLUSIONS: Azithromycin resistance, mainly caused by 23S rRNA C2611T and mtrD mosaics/semi-mosaics, had substantially increased in Brazil. This mostly low-level azithromycin resistance may threaten the recommended ceftriaxone-azithromycin therapy, but the lack of ceftriaxone resistance is encouraging. Enhanced gonococcal AMR surveillance, including WGS, is imperative in Brazil and other Latin American and Caribbean countries.
引用
- Golparian D, Bazzo ML, Ahlstrand J, et al. Recent dynamics in Neisseria gonorrhoeae genomic epidemiology in Brazil: antimicrobial resistance and genomic lineages in 2017-20 compared to 2015-16. J Antimicrob Chemother. 2024. PMID: 38517452. doi:10.1093/jac/dkae075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。